Literature DB >> 25187541

Induction of viral, 7-methyl-guanosine cap-independent translation and oncolysis by mitogen-activated protein kinase-interacting kinase-mediated effects on the serine/arginine-rich protein kinase.

Michael C Brown1, Jeffrey D Bryant1, Elena Y Dobrikova1, Mayya Shveygert1, Shelton S Bradrick2, Vidyalakshmi Chandramohan3, Darell D Bigner3, Matthias Gromeier4.   

Abstract

UNLABELLED: Protein synthesis, the most energy-consuming process in cells, responds to changing physiologic priorities, e.g., upon mitogen- or stress-induced adaptations signaled through the mitogen-activated protein kinases (MAPKs). The prevailing status of protein synthesis machinery is a viral pathogenesis factor, particularly for plus-strand RNA viruses, where immediate translation of incoming viral RNAs shapes host-virus interactions. In this study, we unraveled signaling pathways centered on the ERK1/2 and p38α MAPK-interacting kinases MNK1/2 and their role in controlling 7-methyl-guanosine (m(7)G) "cap"-independent translation at enterovirus type 1 internal ribosomal entry sites (IRESs). Activation of Raf-MEK-ERK1/2 signals induced viral IRES-mediated translation in a manner dependent on MNK1/2. This effect was not due to MNK's known functions as eukaryotic initiation factor (eIF) 4G binding partner or eIF4E(S209) kinase. Rather, MNK catalytic activity enabled viral IRES-mediated translation/host cell cytotoxicity through negative regulation of the Ser/Arg (SR)-rich protein kinase (SRPK). Our investigations suggest that SRPK activity is a major determinant of type 1 IRES competency, host cell cytotoxicity, and viral proliferation in infected cells. IMPORTANCE: We are targeting unfettered enterovirus IRES activity in cancer with PVSRIPO, the type 1 live-attenuated poliovirus (PV) (Sabin) vaccine containing a human rhinovirus type 2 (HRV2) IRES. A phase I clinical trial of PVSRIPO with intratumoral inoculation in patients with recurrent glioblastoma (GBM) is showing early promise. Viral translation proficiency in infected GBM cells is a core requirement for the antineoplastic efficacy of PVSRIPO. Therefore, it is critically important to understand the mechanisms controlling viral cap-independent translation in infected host cells.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25187541      PMCID: PMC4249076          DOI: 10.1128/JVI.01883-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  A nucleo-cytoplasmic SR protein functions in viral IRES-mediated translation initiation.

Authors:  Kristin M Bedard; Sarah Daijogo; Bert L Semler
Journal:  EMBO J       Date:  2006-12-21       Impact factor: 11.598

2.  Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones.

Authors:  Xiang-Yang Zhong; Jian-Hua Ding; Joseph A Adams; Gourisankar Ghosh; Xiang-Dong Fu
Journal:  Genes Dev       Date:  2009-02-15       Impact factor: 11.361

3.  The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site.

Authors:  Melinda K Merrill; Matthias Gromeier
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

Authors:  Jann N Sarkaria; Brett L Carlson; Mark A Schroeder; Patrick Grogan; Paul D Brown; Caterina Giannini; Karla V Ballman; Gaspar J Kitange; Abjahit Guha; Ajay Pandita; C David James
Journal:  Clin Cancer Res       Date:  2006-04-01       Impact factor: 12.531

5.  Subcellular relocalization of a trans-acting factor regulates XIAP IRES-dependent translation.

Authors:  Stephen M Lewis; Anne Veyrier; Nicoleta Hosszu Ungureanu; Sophie Bonnal; Stéphan Vagner; Martin Holcik
Journal:  Mol Biol Cell       Date:  2007-02-07       Impact factor: 4.138

6.  Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation.

Authors:  Assen Marintchev; Katherine A Edmonds; Boriana Marintcheva; Elthea Hendrickson; Monika Oberer; Chikako Suzuki; Barbara Herdy; Nahum Sonenberg; Gerhard Wagner
Journal:  Cell       Date:  2009-02-06       Impact factor: 41.582

7.  Poly(A)-binding protein is differentially required for translation mediated by viral internal ribosome entry sites.

Authors:  Shelton S Bradrick; Elena Y Dobrikova; Constanze Kaiser; Mayya Shveygert; Matthias Gromeier
Journal:  RNA       Date:  2007-07-25       Impact factor: 4.942

8.  Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites.

Authors:  Sylvain de Breyne; Yingpu Yu; Anett Unbehaun; Tatyana V Pestova; Christopher U T Hellen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

9.  Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo.

Authors:  Constanze Kaiser; Elena Y Dobrikova; Shelton S Bradrick; Mayya Shveygert; James T Herbert; Matthias Gromeier
Journal:  RNA       Date:  2008-08-28       Impact factor: 4.942

10.  Identification of gemin5 as a novel 7-methylguanosine cap-binding protein.

Authors:  Shelton S Bradrick; Matthias Gromeier
Journal:  PLoS One       Date:  2009-09-14       Impact factor: 3.240

View more
  25 in total

1.  Restriction of Replication of Oncolytic Herpes Simplex Virus with a Deletion of γ34.5 in Glioblastoma Stem-Like Cells.

Authors:  Cole Peters; Max Paget; Kizito-Tshitoko Tshilenge; Dipongkor Saha; Slawomir Antoszczyk; Anouk Baars; Thomas Frost; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

2.  MNK inversely regulates TELO2 vs. DEPTOR to control mTORC1 signaling.

Authors:  Michael C Brown; Matthias Gromeier
Journal:  Mol Cell Oncol       Date:  2017-03-17

3.  Recombinant poliovirus for cancer immunotherapy.

Authors:  Millena Prata Jammal; Márcia Antoniazi Michelin; Rosekeila Simões Nomelini; Eddie Fernando Candido Murta
Journal:  Ann Transl Med       Date:  2018-09

4.  Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas.

Authors:  Vidyalakshmi Chandramohan; Jeffrey D Bryant; Hailan Piao; Stephen T Keir; Eric S Lipp; Michaela Lefaivre; Kathryn Perkinson; Darell D Bigner; Matthias Gromeier; Roger E McLendon
Journal:  Arch Pathol Lab Med       Date:  2017-08-22       Impact factor: 5.534

Review 5.  Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus.

Authors:  Michael C Brown; Matthias Gromeier
Journal:  Discov Med       Date:  2015-05       Impact factor: 2.970

6.  Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncolysis.

Authors:  Michael C Brown; Mikhail I Dobrikov; Matthias Gromeier
Journal:  J Virol       Date:  2014-09-03       Impact factor: 5.103

7.  Regulation of Hypoxia-Inducible Factor 1α during Hypoxia by DAP5-Induced Translation of PHD2.

Authors:  Jeffrey D Bryant; Michael C Brown; Mikhail I Dobrikov; Elena Y Dobrikova; Sarah L Gemberling; Qing Zhang; Matthias Gromeier
Journal:  Mol Cell Biol       Date:  2018-05-15       Impact factor: 4.272

8.  Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs.

Authors:  Michael C Brown; Eda K Holl; David Boczkowski; Elena Dobrikova; Mubeen Mosaheb; Vidya Chandramohan; Darell D Bigner; Matthias Gromeier; Smita K Nair
Journal:  Sci Transl Med       Date:  2017-09-20       Impact factor: 17.956

9.  Ribosomal RACK1:Protein Kinase C βII Phosphorylates Eukaryotic Initiation Factor 4G1 at S1093 To Modulate Cap-Dependent and -Independent Translation Initiation.

Authors:  Mikhail I Dobrikov; Elena Y Dobrikova; Matthias Gromeier
Journal:  Mol Cell Biol       Date:  2018-09-14       Impact factor: 4.272

Review 10.  Recombinant Poliovirus for Cancer Immunotherapy.

Authors:  Matthias Gromeier; Smita K Nair
Journal:  Annu Rev Med       Date:  2018-01-29       Impact factor: 13.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.